# PVLA catalysts: PALVELLA THERAPEUTICS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/pvla/catalysts

> PALVELLA THERAPEUTICS, INC. (PVLA) has 4 upcoming catalysts. The next is the rapamycin PDUFA date, February 28, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for PVLA?

PALVELLA THERAPEUTICS, INC. (PVLA) has 4 upcoming catalysts. The next is the rapamycin PDUFA date, February 28, 2027. Press release filed with the SEC (EX-99): "FDA Accepts NDA for QTORIN Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027" [Calendar and source filings](https://sec-api.dev/companies/pvla/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-448594, https://www.sec.gov/Archives/edgar/data/1583648/000119312526448594/pvla-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/pvla/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | PALVELLA THERAPEUTICS, INC. |
| Ticker | PVLA (Nasdaq) |
| SEC CIK | 1583648 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/pvla |

## Cash runway

Cash $236.7M as of 2026-09-30; quarterly burn $14.4M; about 49.2 months of runway at that rate (XBRL company facts, accession 0001193125-26-448638).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2023 | [BOS-342 trial start](https://sec-api.dev/pdufa/bos-342) | PVLA |  | completed | "In August 2023, the first patient was dosed in the Boston Pharmaceuticals sponsored Phase 1/2 study for BOS-342 in hepatocellular carcinoma, or HCC, for which the Company received a milestone payment." ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm)) |
| Q4 2024 | [Rapamycin trial start](https://sec-api.dev/pdufa/rapamycin) | PVLA |  | scheduled | "We plan to initiate our Phase 2 clinical trial, a 12-week, multicenter, baseline-controlled Phase 2 clinical trial of QTORIN rapamycin in up to 20 patients with cutaneous venous malformations in the 4th quarter of 2024." ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm)) |
| Nov 2024 | [Rapamycin trial start](https://sec-api.dev/pdufa/rapamycin) | PVLA |  | completed | "In November 2024, Palvella dosed the first patient in the Phase 3 SELVA study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025047206/pvla-ex99_1.htm)) |
| December 31, 2024 | [PALVELLA THERAPEUTICS, INC. interim data readout](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | scheduled | "Interim results for the three and nine months ended September 30, 2024 are not necessarily indicative of results that may be expected for the year ending December 31, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1583648/000143774924034891/pirs20240930_10q.htm)) |
| March 31, 2025 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025047206/pvla-ex99_1.htm)) |
| May 15, 2025 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025071988/pvla-ex99_1.htm)) |
| August 14, 2025 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/pvla-ex99_1.htm)) |
| Q4 2025 | [Rapamycin topline data readout](https://sec-api.dev/pdufa/rapamycin) | PVLA | cutaneous venous malformations | scheduled | "Top-line results for Phase 2 TOIVA trial evaluating QTORIN rapamycin for cutaneous venous malformations remain on track for the fourth quarter of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/pvla-ex99_1.htm)) |
| Q4 2025 | [PALV-10 topline data readout](https://sec-api.dev/pdufa/palv-10) | PVLA |  | scheduled | "We expect to report top-line data for the TOIVA (PALV-10) study in the fourth quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm)) |
| November 10, 2025 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312525274378/pvla-ex99_1.htm)) |
| November 21, 2025 | [Qtorin 3.9% rapamycin anhydrous gel primary completion](https://sec-api.dev/pdufa/qtorin-3-9-rapamycin-gel) | PVLA | Cutaneous Venous Malformations | completed | "NCT06653842 (A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-11-21 (ACTUAL); Lead Sponsor Palvella Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06653842)) |
| Dec 2025 | [PALVELLA THERAPEUTICS, INC. topline data readout](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | scheduled | "Top-line results from TOIVA are on track for mid-December 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312525274378/pvla-ex99_1.htm)) |
| December 15, 2025 | [Rapamycin topline data readout](https://sec-api.dev/pdufa/rapamycin) | PVLA |  | completed, positive | "2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced positive topline results from the Company's Phase 2 TOIVA study of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000110465925120789/tm2533458d1_ex99-2.htm)) |
| Q1 2026 | [PALVELLA THERAPEUTICS, INC. topline data readout](https://sec-api.dev/companies/pvla/catalysts) | PVLA | microcystic LM | scheduled | "We expect to report top-line data for the Phase 3 study in the first quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1583648/000119312525276119/pvla-20250930.htm)) |
| Q1 2026 | [PALVELLA THERAPEUTICS, INC. topline data readout](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | scheduled | "We expect to report top-line data from this trial in the first quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm)) |
| Q1 2026 | [Rapamycin topline data readout](https://sec-api.dev/pdufa/rapamycin) | PVLA | microcystic LM | scheduled | "Phase 3 SELVA trial evaluating QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line results on track for the first quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/pvla-ex99_1.htm)) |
| January 14, 2026 | [Qtorin 3.9% rapamycin anhydrous gel primary completion](https://sec-api.dev/pdufa/qtorin-3-9-rapamycin-gel) | PVLA | Microcystic Lymphatic Malformation | completed | "NCT06239480 (SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-14 (ACTUAL); Lead Sponsor Palvella Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06239480)) |
| February 24, 2026 | [Rapamycin topline data readout](https://sec-api.dev/pdufa/rapamycin) | PVLA |  | completed, positive | "WAYNE, Pa., February 24, 2026 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat participants suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced positive topline results from the Company's Phase 3 SELVA study of QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526065159/pvla-ex99_1.htm)) |
| Mar 2026 | [Rapamycin NDA/BLA submission](https://sec-api.dev/pdufa/rapamycin) | PVLA |  | completed | "In March 2026, we submitted a pre-NDA meeting request to" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1583648/000119312526210463/pvla-20260331.htm)) |
| March 31, 2026 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/pvla-ex99_1.htm)) |
| Q2 2026 | [Rapamycin trial start](https://sec-api.dev/pdufa/rapamycin) | PVLA | clinically significant angiokeratomas planned for second quarter of 2026 | scheduled | "Initiation of Phase 2 trial of QTORIN rapamycin for the treatment of clinically significant angiokeratomas planned for second quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/pvla-ex99_1.htm)) |
| May 7, 2026 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_1.htm)) |
| Jun 2026 | [Rapamycin NDA/BLA submission](https://sec-api.dev/pdufa/rapamycin) | PVLA |  | completed | "In June 2026, we submitted the first module of our rolling NDA, and in August 2026, we completed the rolling submission." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1583648/000119312526448638/pvla-20260930.htm)) |
| 2H 2026 | [Rapamycin NDA/BLA submission](https://sec-api.dev/pdufa/rapamycin) | PVLA | microcystic LM | scheduled | "Palvella plans to submit a New Drug Application to the U.S. FDA for QTORIN rapamycin for Microcystic LMs in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526232717/pvla-ex99_1.htm)) |
| 2H 2026 | [ZYPITAMAG® (pitavastatin) trial start](https://sec-api.dev/pdufa/pitavastatin) | PVLA | disseminated superficial actinic porokeratosis planned for second half of 2026 | scheduled | "Initiation of Phase 2 trial of QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis planned for the second half of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_1.htm)) |
| August 4, 2026 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_1.htm)) |
| Q4 2026 | [Rapamycin trial start](https://sec-api.dev/pdufa/rapamycin) | PVLA | cutaneous venous malformations planned for second half of 2026 | scheduled | "Initiation of Phase 3 trial of QTORIN rapamycin for the treatment of cutaneous venous malformations planned for the fourth quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_1.htm)) |
| October 28, 2026 | [Rapamycin NDA/BLA acceptance](https://sec-api.dev/pdufa/rapamycin) | PVLA | microcystic lymphatic malformations | completed | "On October 28, 2026, Palvella Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has accepted for filing and granted Priority Review to the Company's New Drug Application for QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1583648/000119312526435113/pvla-20261028.htm)) |
| November 5, 2026 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526448594/pvla-ex99_1.htm)) |
| February 28, 2027 | [Rapamycin PDUFA date](https://sec-api.dev/pdufa/rapamycin) | PVLA |  | scheduled | "FDA Accepts NDA for QTORIN Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526448594/pvla-ex99_1.htm)) |
| 2H 2027 | [Rapamycin topline data readout](https://sec-api.dev/pdufa/rapamycin) | PVLA |  | scheduled | "Topline results from LOTU are expected in the second half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526448594/pvla-ex99_1.htm)) |
| August 2027 | [PTX-022 primary completion](https://sec-api.dev/pdufa/ptx-022) | PVLA | Angiokeratomas | scheduled | "NCT07552077 (A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Palvella Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07552077)) |
| Aug to Nov 2027 | [PTX-022 topline data readout](https://sec-api.dev/pdufa/ptx-022) | PVLA | Angiokeratomas | scheduled | "NCT07552077 (A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Palvella Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07552077)) |

## Drugs

- [BOS-342](https://sec-api.dev/pdufa/bos-342): 
- [PALV-10](https://sec-api.dev/pdufa/palv-10): 
- [PTX-022](https://sec-api.dev/pdufa/ptx-022): Angiokeratomas
- [Qtorin 3.9% rapamycin anhydrous gel](https://sec-api.dev/pdufa/qtorin-3-9-rapamycin-gel): Microcystic Lymphatic Malformation, Cutaneous Venous Malformations
- [Rapamycin](https://sec-api.dev/pdufa/rapamycin): cutaneous vms, cutaneous venous malformations, microcystic lm, microcystic lms in patients 3 years and older, microcystic lymphatic malformations

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/pvla/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PVLA catalysts: PALVELLA THERAPEUTICS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/pvla/catalysts

```bibtex
@misc{secapidev_companies_pvla_catalysts_20261116,
  title        = {PVLA catalysts: PALVELLA THERAPEUTICS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/pvla/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_pvla_catalysts_20261116","title":"PVLA catalysts: PALVELLA THERAPEUTICS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/pvla/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
